von Jörg B. Schulz ; Peter Berlit ; Hans-Christoph Diener ; Christian Gerloff ; Andreas Greinacher ; Christine Klein ; Gabor C. Petzold ; Marco Piccininni ; Sven Poli ; Rainer Röhrig ; Helmuth Steinmetz ; Thomas Thiele ; Tobias Kurth ; Karsten Witt
von Philipp Eckert ; Philine Marchetta ; Marie Kristin Manthey ; Michael H. Walter ; Saša Jovanović ; Daria Savitska ; Wibke Singer ; Michele H. Jacob ; Lukas Rüttiger ; Thomas Schimmang ; Ivan Milenković ; Peter K. D. Pilz ; Marlies Knipper
Online first: 8 January 2021 ; Gesehen am 16.07.2021
First-line therapy for younger patients with peripheral T-cell non-Hodgkin lymphoma (T-NHL) consists of 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without etoposide (CHOEP), consolidated by high-dose therapy and autologous stem cell transplantation (auto-SCT). We hypothesized that allogeneic stem cell transplantation (allo-SCT) could improve outcomes. 104 patients with peripheral T-cell non-Hodgkin lymphoma, except ALK+ anaplastic large cell lymphoma, 18 to 60 years, all stages, and all age adjusted International Prognostic Index scores, except 0 and stage I, were randomized to 4 cycles of CHOEP and 1 cycle of dexamethasone, cytosine-arabinoside, and platinum (DHAP) followed by high-dose therapy and auto-SCT or myeloablative conditioning and allo-SCT. The primary end point was event-free survival (EFS) at 3 years. After a median follow-up of 42 months, the 3-year EFS after allo-SCT was 43%, as compared with 38% after auto-SCT. Overall survival at 3 years was 57% vs 70% after allo- or auto-SCT, without significant differences between treatment arms. None of the 21 responding patients proceeding to allo-SCT relapsed, as opposed to 13 of 36 patients (36%) proceeding to auto-SCT. Eight of 26 patients (31%) and none of 41 patients died of transplant-related toxicity after allo- and auto-SCT, respectively. The strong graft-versus-lymphoma effect after allo-SCT was counterbalanced by transplant-related mortality. This trial is registered at www.clinicaltrials.gov as #NCT00984412.
Blood Washington, DC : American Society of Hematology, 1946 137(2021), 19 vom: 13. Mai, Seite 2646-2656 Online-Ressource
von Soyeon Bae ; Lea Heidrich ; Shaun R. Levick ; Martin M. Gossner ; Sebastian Seibold ; Wolfgang W. Weisser ; Paul Magdon ; Alla Serebryanyk ; Claus Bässler ; Deborah Schäfer ; Ernst-Detlef Schulze ; Inken Dörfler ; Jörg Müller ; Kirsten Jung ; Marco Heurich ; Markus Fischer ; Nicolas Roth ; Peter Schall ; Steffen Boch ; Stephan Wöllauer ; Swen C. Renner ; Jörg Müller
von Christian Deppner ; Waldemar Herr ; Merle Cornelius ; Peter Stromberger ; Tammo Sternke ; Christoph Grzeschik ; Alexander Grote ; Jan Rudolph ; Sven F. Herrmann ; Markus Krutzik ; André Wenzlawski ; Robin Corgier ; Eric Charron ; David Guéry-Odelin ; Naceur Gaaloul ; Claus Lämmerzahl ; Achim Peters ; Patrick Windpassinger ; Ernst Maria Rasel
von Daniel Thomas-Rüddel ; Peter Hoffmann ; Daniel Schwarzkopf ; Christian Scheer ; Friedhelm Bach ; Marcus Komann ; Herwig Gerlach ; Manfred Weiss ; Matthias Lindner ; Hendrik Rüddel ; Philipp Simon ; Sven-Olaf Kuhn ; Reinhard Wetzker ; Michael Bauer ; Konrad Reinhart ; Frank Bloos ; Anja Diers ; Florian Jelschen ; Andreas Weyland
von Antonietta De Sio ; Ephraim Sommer ; Xuan Trung Nguyen ; Lynn Groß ; Duško Popović ; Benjamin Tyler Nebgen ; Sebastian Fernandez-Alberti ; Stefano Pittalis ; Carlo Andrea Rozzi ; Elisa Molinari ; Elena Mena-Osteritz ; Peter Bäuerle ; Thomas Frauenheim ; Sergei Tretiak ; Christoph Lienau
Seite 39 von 295
